Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 457Pancreatic Neoplasms 364Stomach Neoplasms 246Carcinoma, Hepatocellular 231Carcinoma, Non-Small-Cell Lung 165Colonic Neoplasms 146Esophageal Neoplasms 133Neoplasms 115Neoplasm Metastasis 115Ovarian Neoplasms 111Rectal Neoplasms 107Liver Neoplasms 101Breast Neoplasms 99Lung Neoplasms 79Melanoma 76Squamous Cell Carcinoma of Head and Neck 70Gastrointestinal Neoplasms 58Endometrial Neoplasms 58Carcinoma, Renal Cell 54Uterine Cervical Neoplasms 52Cholangiocarcinoma 52Biliary Tract Neoplasms 52Triple Negative Breast Neoplasms 49Head and Neck Neoplasms 48Sarcoma 46Prostatic Neoplasms 45Esophageal Squamous Cell Carcinoma 39Urinary Bladder Neoplasms 34Small Cell Lung Carcinoma 31Carcinoma 29

Interventions

regorafenib 1napabucasin 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Gastrointestinal Cancer × Gastrointestinal × Clear all
NCT02024607 2023-11-15

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
495 enrolled 18 charts
Gastrointestinal

Advanced Gastrointestinal Cancer

NCT02008539 2017-03-27

TREAT-ME 1

Apceth GmbH & Co. KG

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Advanced Gastrointestinal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡